Current and Future Directions for Angiosarcoma Therapy

Vaia Florou, Breelyn A Wilky

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.

Original languageEnglish (US)
Article number14
JournalCurrent Treatment Options in Oncology
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Hemangiosarcoma
Therapeutics
Vascular Neoplasms
Clinical Trials
Taxoids
Genetic Heterogeneity
Anthracyclines
Combination Drug Therapy
Sarcoma
Protein-Tyrosine Kinases
Immunotherapy
Direction compound
Biomarkers
Recurrence
Drug Therapy
Antibodies
Neoplasms

Keywords

  • Angiosarcoma
  • Chemotherapy
  • Clinical trials
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Current and Future Directions for Angiosarcoma Therapy. / Florou, Vaia; Wilky, Breelyn A.

In: Current Treatment Options in Oncology, Vol. 19, No. 3, 14, 01.03.2018.

Research output: Contribution to journalReview article

@article{f21e9304a00043d88a95306602df9508,
title = "Current and Future Directions for Angiosarcoma Therapy",
abstract = "Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.",
keywords = "Angiosarcoma, Chemotherapy, Clinical trials, Immunotherapy, Targeted therapy",
author = "Vaia Florou and Wilky, {Breelyn A}",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s11864-018-0531-3",
language = "English (US)",
volume = "19",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Current and Future Directions for Angiosarcoma Therapy

AU - Florou, Vaia

AU - Wilky, Breelyn A

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.

AB - Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.

KW - Angiosarcoma

KW - Chemotherapy

KW - Clinical trials

KW - Immunotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85043319847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043319847&partnerID=8YFLogxK

U2 - 10.1007/s11864-018-0531-3

DO - 10.1007/s11864-018-0531-3

M3 - Review article

C2 - 29520447

AN - SCOPUS:85043319847

VL - 19

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 3

M1 - 14

ER -